• PDF / 168,960 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 10 Downloads / 156 Views

DOWNLOAD

REPORT

---

1 S

Certolizumab-pegol Neutropenia: case report

In a single-center, retrospective cohort study of 281 adult patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor inhibitors (TNFi) at a tertiary care center conducted between 2007 and 2018, a patient [exact age and sex not stated] was described, who developed neutropenia during treatment with certolizumab pegol for inflammatory bowel disease [dosage, route, duration of treatment to reaction onset and outcome not stated]. The patient, who had IBD, received treatment with certolizumab-pegol. Subsequently, the patient developed neutropenia. Alaskar D, et al. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. Saudi Journal of Gastroenterology 26: 210-215, No. 4, Aug 2020. Available from: URL: http://doi.org/10.4103/sjg.SJG_41_20

0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803505529

Reactions 10 Oct 2020 No. 1825